Here’s How Your Trade ADMA Biologics Inc. (ADMA) Aggressively Right Now – News Heater
Home  »  Companies   »  Here’s How Your Trade ADMA Biologics Inc. (A...

Here’s How Your Trade ADMA Biologics Inc. (ADMA) Aggressively Right Now

ADMA Biologics Inc. (NASDAQ:ADMA) went down by -11.18% from its latest closing price compared to the recent 1-year high of $2.15. The company’s stock price has collected -27.78% of loss in the last five trading sessions.

Is It Worth Investing in ADMA Biologics Inc. (NASDAQ :ADMA) Right Now?

Plus, the 36-month beta value for ADMA is at 1.07. Opinions of the stock are interesting as 2 analysts out of 2 who provided ratings for ADMA Biologics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


The average price from analysts is $4.75, which is $3.69 above the current price. ADMA currently public float of 177.10M and currently shorts hold a 12.97% ratio of that float. Today, the average trading volume of ADMA was 2.50M shares.

ADMA’s Market Performance

ADMA stocks went down by -27.78% for the week, with a monthly drop of -27.78% and a quarterly performance of -14.37%, while its annual performance rate touched -14.37%. The volatility ratio for the week stands at 9.85% while the volatility levels for the past 30 days are set at 7.25% for ADMA Biologics Inc.. The simple moving average for the period of the last 20 days is -25.52% for ADMA stocks with a simple moving average of -3.76% for the last 200 days.

Analysts’ Opinion of ADMA

Many brokerage firms have already submitted their reports for ADMA stocks, with Raymond James repeating the rating for ADMA by listing it as a “Strong Buy.” The predicted price for ADMA in the upcoming period, according to Raymond James is $5 based on the research report published on November 11th of the previous year 2021.

Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see ADMA reach a price target of $4.50. The rating they have provided for ADMA stocks is “Overweight” according to the report published on November 09th, 2021.

Jefferies gave a rating of “Buy” to ADMA, setting the target price at $8 in the report published on June 04th of the previous year.

ADMA Trading at -21.42% from the 50-Day Moving Average

After a stumble in the market that brought ADMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.64% of loss for the given period.

Volatility was left at 7.25%, however, over the last 30 days, the volatility rate increased by 9.85%, as shares sank -28.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.80% lower at present.

During the last 5 trading sessions, ADMA fell by -27.78%, which changed the moving average for the period of 200-days by -13.33% in comparison to the 20-day moving average, which settled at $1.8915. In addition, ADMA Biologics Inc. saw 1.42% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ADMA starting from Grossman Adam S, who purchase 250,000 shares at the price of $1.00 back on Oct 25. After this action, Grossman Adam S now owns 1,128,444 shares of ADMA Biologics Inc., valued at $250,000 using the latest closing price.

Grossman Adam S, the President and CEO of ADMA Biologics Inc., purchase 100,000 shares at $1.00 during a trade that took place back on Oct 25, which means that Grossman Adam S is holding 2,137,616 shares at $100,000 based on the most recent closing price.

Stock Fundamentals for ADMA

Current profitability levels for the company are sitting at:

  • -72.41 for the present operating margin
  • +0.57 for the gross margin

The net margin for ADMA Biologics Inc. stands at -88.52. Equity return is now at value -61.20, with -29.10 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 6.87.

Leave a Comment

Your email address will not be published.




Download Free eBook For


100% free. stop anytime no spam